Integra LifeSciences – Limit Uncertainty
Integra LifeSciences (IART) is a multinational corporation providing medical devices supporting wide array of surgical needs. Their strategic intent is to become the worldwide leader in in orthopedic extremity surgery, neurosurgery, spine surgery, and reconstructive and general surgery. Their innovative offerings and growth through acquisition has allowed them to become a billion dollar enterprise since their inception in 1989 (“IART profile”). They are headquartered in Plainsboro, New Jersey and have 3,300 employees worldwide (“Company profile,” 2014). Integra's common stock is listed on The NASDAQ Stock Market under the symbol "IART." Integra’s target markets reside in the United States, European Union, Asia Pacific, BRIC (Brazil, Russia, India and China) and Latin America.
Integra's business model is matrix broken down into divisions supporting extremities, spine, neurosurgery, and international. This allows them to focus on core competencies while responding to local needs. Their broad portfolio of products include orthopedics, implants and hospital equipment used in neurosurgery, neuromonitoring, neurotrauma, and related critical care. Integra’s primary markets are within the U.S., where approximately 75% of revenue is generated (“Integra lifesciences reports,” 2014).
Integra’s growth from 1989 through 2014 has been driven using an acquisition model. During this time, Integra has completed over 40 acquisitions. This model has limited organic growth as most of their new product introductions surround derivative improvements of existing products. Their most recent acquisition was their largest. They consummated a deal with Covidien to acquire DuraSeal for $235 million in...
... middle of paper ...
...ant System. Retrieved May 3, 2014, from http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/DeviceApprovalsandClearances/Recently-ApprovedDevices/ucm185478.htm
Gerber, J. (2011). International economics. (5th ed.). Upper Saddle River, NJ: Prentice
IART Profile. (n.d.). . Retrieved May 3, 2014, from http://finance.yahoo.com/q/pr?s=IART+Profile
Integra LifeSciences Completes Acquisition of DuraSeal Product Lines From Covidien. (January 15, 2014). . Retrieved May 2, 2014, from http://globenewswire.com/news-release/2014/01/15/602722/10064277/en/Integra-LifeSciences-Completes-Acquisition-of-DuraSeal-Product-Lines-From-Covidien.html
Integra LifeSciences Reports First Quarter 2014 Financial Results. (May 1, 2014). MarketWatch. Retrieved May 3, 2014, from http://www.marketwatch.com/story/integra-lifesciences-reports-first-quarter-2014-financial-results-2014-05-01
Transcatheter aortic valve replacement or TAVR is the latest technology used principally for the treatment of aortic stenosis, a condition in which one of the major valves of the heart, the aortic valve, becomes tight and stiff, usually as a result of aging (3). Since many patients who need aortic valve replacement for aortic stenosis are too sick to undergo major valve replacement surgery, they are unable to get the treatment they need. With the transcatheter aortic valve, this issue is bypassed because this valve can be implanted in the heart by accessing the patient’s heart through an artery in the groin. The valve can be inserted through a wire that can be pushed to the heart and the old valve is simply pushed to the side when the new valve is implanted. This technology has been in use in the US with Edwards’ Sapiens valve since 2011 and has saved the lives of many patients with aortic stenosis (4). Medtronic’s CoreValve uses similar technology and has won patent fights in Europe and has been in use internationally. However, within U.S., Medtronic has not been...
The CNS Company is already a successful company due to the achievements of its breathing right strips. In my analysis we learned that they already do a lot of things right. What they need to be aware of is the different economical situations in the global marketplace, there are different ways that the product is approved abroad, and there is competition lurking. CNS needs to continue to leverage their strengths, but capitalize on their opportunities and benchmark the competition.
Brauna Technologies has a long history of successful orthopedic contributions. Our quality and technical assurance standards exceed those used by industry and government regulators. The company’s culture connections began with Dr. von Kastner’s orthopedic fracture repair skills during the World War II when German soldiers’ arms and legs were shattered as a result of the war. Dr. von Kastner a strong succession plan to lead the company.
“US Markets for Heart Valves.” SAGE Sourcebook of Modern Biomedical Devices: Business Environments, 2007. 21 April 2011.
First of all we need to understand the type of technology this device represents. Is this a sustaining innovation? Or is this a completely new disruptive product? After fully understanding this aspect we can make better decisions regarding the future of the firm and its product. This device offers many benefits that current products do not. As explained earlier, this device is extremely portable, offering emergency rooms the flexibility and convenience they seek to provide patients with the best treatment possible. Likewise, this product will come in at a price point much lower than current echocardiographies, further separ...
The Clorox Company. (2014, February 4). The Clorox Company Reports Slight Sales Growth on Top of Strong Year-Ago Results; Updates Fiscal Year 2014 Outlook. Retrieved March 21, 2014, from http://investors.thecloroxcompany.com/releasedetail.cfm?ReleaseID=822888
Exxon Mobil Corporation Financial Statements and Supplemental Information. (31 Dec, 2010). Retrieved on 17 Nov, 2011 from
Annual Report 2012 Costco Wholesale: Year Ended September 2, 2012 [PDF document]. 1-7. Retrieved from Costco Wholesale Financial Reports:
Over the past decade, scientists have made significant advancements in the treatment of certain diseases. Unfortunately, just like any new product, the cost of developing these new technologies and treatments is extremely high. Plus, unlike other technology, heath technolo...
Fortune 100 Best Companies To Work For. (2014, February 3). Fortune 100 Best Companies to Work For . Retrieved April 18, 2014, from http://money.cnn.com/magazines/fortune/best-companies/2014/snapshots/75.html?iid=BC14_lp_arrow1
middle of paper ... ... In the end, Novartis has a very strong internal environment. Their strategic direction, value chain, strengths, resources, and capabilities have allowed them to grow, develop, and truly become a global leader in the pharmaceutical industry. Novartis is currently one of the largest companies in the pharmaceutical industry, for both generic and brand name medications.
Janssen is a division of Johnson and Johnsons that primarily focus on diseases that can help develop new strategies in improving prevention as well as developing vaccines and its accessibility to the world. The pharmaceutical company of J&J invests large amounts of money in research and development of its products. The competitive environment of Johnson and Johnson is very high for pharmaceutical companies due to which that many companies are releasing drug products and other devices. However, this company does not face any potential competitors due to which that it is a large company that provides a wide range of opportunities such as finances, and experiences. This leads to advantages compared to other competitors due to whom the pharmaceutical companies creates a barrier because of the high cost in research and development in medicine. In addition, Johnson and Johnson have to make sure that it has many suppliers for different categories for their products especially in medicine if one supplier causes shortages. Although suppliers do not bargain for the price values of its products, it still influences the price in the market in different countries. In addition, finding
...d about the economic nature of new technologies, Dr. Slez emphasized that “costs almost always increase with new equipment”. When deciding whether or not to adopt a new technology, Dr. Slez cited cost of implementation, industry standard, and efficacy relevant to the current market as his primary considerations. “If a treatment costs more but is no more effective, we won’t adopt it” he continued. Technology, as with all other aspects of the firm, must be consistent with that firm’s goals; excellent care at an affordable cost.
Hospital for Special Surgery (HSS) is a private hospital that specializes in orthopedic surgery and the treatment of rheumatology conditions. According to the employer handbook, the mission of HSS is to “provide the highest quality patient care, improve mobility, and enhances the quality of life for all and to advance the science of orthopedic surgery, rheumatology, and their related disciplines through research and education. [HSS] does this regardless of race, color, creed, sexual orientation, or ethnic origin”. On the other hand, the vision is to “lead the world as the most innovative source of medical care, the premier research institution, and the most trusted educator in the field of orthopedics, rheumatology, and their related disciplines”. (Employee Handbook, 2016)
There are several external growth methods that entrepreneurs may choose for growing their business which are ‘a merger with’ or ‘acquisition of’ other companies.